SCHEMBL2165046

SCHEMBL2165046

Cc1ccc(C[C@@](C)(O)C(=O)O)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 3/20 0.43
CCR2 P41597 1/20 0.42
FDPS P14324 1/20 0.41
CA2 P00918 2/20 0.40
CA1 P00915 1/20 0.40
MAPT P10636 5/20 0.40
HPGD P15428 5/20 0.40
GAA P10253 3/20 0.40
CYP3A4 P08684 3/20 0.40
CYP1A2 P05177 3/20 0.40
POLB P06746 2/20 0.40
ALOX15 P16050 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
EGFR P00533 1/20 0.40
FYN P06241 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2165043 1.00 ALDH1A1 (0.43) ALDH1A1NPSR1KDM4ECCR2FDPS
SCHEMBL2166179 0.81 HPGD (0.41) ALDH1A1KDM4EMAPTHPGDGAA
SCHEMBL2166173 0.81 HPGD (0.41) ALDH1A1KDM4EMAPTHPGDGAA
SCHEMBL1205603 0.78 KDM4E (0.33) ALDH1A1KDM4ECA2CA1MAPT
SCHEMBL1205600 0.78 KDM4E (0.33) ALDH1A1KDM4ECA2CA1MAPT
SCHEMBL2163986 0.78 MCL1 (0.40) ALDH1A1KDM4EHPGDCYP3A4ALOX15
SCHEMBL2163990 0.78 MCL1 (0.40) ALDH1A1KDM4EHPGDCYP3A4ALOX15
SCHEMBL9917301 0.77 CYP3A4 (0.48) ALDH1A1NPSR1KDM4ECCR2FDPS
SCHEMBL13599422 0.74 SLC6A2 (0.57) ALDH1A1NPSR1KDM4ECCR2FDPS
SCHEMBL1403495 0.74 CA2 (0.65) ALDH1A1NPSR1KDM4ECCR2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985747-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-26 US disclosed
US-20100249114-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-30 US disclosed
US-7700598-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-20 US disclosed
US-20090176770-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176770-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA ALDH1A1 1335/4885NPSR1 79/4885KDM4E 3751/4885
US-20100249114-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA ALDH1A1 1335/4885NPSR1 79/4885KDM4E 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.